LBO‐02: Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC‐520, an RNAi drug targeting cccDNA derived HBV mRNA

Abstract

Journal of Viral HepatitisVolume 25, Issue S2 p. 190-191 Abstract LBO-02: Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC-520, an RNAi drug targeting cccDNA derived HBV mRNA First published: 12 June 2018 https://doi.org/10.1111/jvh.01_12935Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume25, IssueS2Special Issue: 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) held from June 14th to 17th, 2018, in Toronto, CanadaJune 2018Pages 190-191 RelatedInformation